- Sotagliflozin, a dual sodium-glucose cotransporter type-1 and -2 inhibitor, improves glycemic control and leads to weight reduction in insulin-treated patients with type 1 diabetes (T1D).
Why this matters
- Almost half of patients with T1D are overweight or obese, and a sizable proportion of these patients also have inadequately controlled disease.
- Post hoc analysis that examined the use of sotagliflozin as an adjunct to insulin for glycemic control and weight reduction over a 24-week period in patients with T1D and a baseline body mass index of ≥27 kg/m2.
- Patients were randomly assigned to 3 groups:
- Sotagliflozin 200 mg (n=305);
- Sotagliflozin 400 mg (n=313);
- Insulin alone (n=298).
- Safety endpoints were examined at 52 weeks.
- Funding: Lexicon Pharmaceuticals Inc. and Sanofi.
- Greater reductions in HbA1c with sotagliflozin 200 mg (least mean squares difference [LMSD], −0.39; P<.001 and mg p vs insulin alone.>
- Compared with insulin alone, sotagliflozin was associated with greater reductions in body weight with the 200 mg dose (LMSD, −2.27; P<.001 and the mg dose p>
- Fewer severe hypoglycemia events were observed in the sotagliflozin group.
- Sotagliflozin was associated with a higher diabetic ketoacidosis incidence.
- Relatively short follow-up period and lack of an active comparator drug.